Genetix Biotherapeutics

Focus: Genetix Biotherapeutics is a private gene therapy specialist focused on cellular extraction and reintroduction approaches, headquartered in Somerville, MA with a lean operational footprint targeting rare and serious blood disorders.

Gene Therapy

Profile data last refreshed 2h ago · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Open Jobs

20-3 this month

Stable — net -3 jobs in 30d

5 added, 8 removed. Backfill posture.

Should You Work at Genetix Biotherapeutics?

AI assessment

Strong scientific potential with clinical-stage assets, but career risk depends entirely on upcoming financing and Phase 3 readouts; best suited for individuals seeking early-stage exposure with IPO or acquisition upside.

Why Work Here

Advanced pipeline with 5 Phase 3 programs and 6 Phase 2 programs across high-impact indications (beta-thalassemia, sickle cell disease, CALD) offering clinical validation exposure.

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of

Sickle-cell Disease (SCD)

N/A

Clinical Trials (1)

NCT04413539Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living with Sickle- Cell Disease in France

N/A

Help build intelligence for Genetix Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Actively hiring 23 roles with strong emphasis on Quality Assurance (6), Patient Supply (3), and Commercial (3) indicates imminent commercialization readiness.

Gene therapy and cellular therapy modalities represent cutting-edge biotech science with substantial intellectual property upside in high-need rare disease markets.

Watch Out For

Private status with no disclosed funding or revenue introduces uncertainty around runway, valuation, and exit timeline—typical pre-commercial biotech risk.
Lean headcount and absence of published data suggest early-stage organization lacking mature infrastructure, potentially limiting mentorship and career development resources.

Generated by Claude from Genetix Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Safety and efficacy assessments

Sickle Cell Disease

N/A

Clinical Trials (1)

NCT04628585Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy

N/A

Safety and efficacy assessments

Transfusion-dependent Beta-Thalassemia

N/A

Clinical Trials (1)

NCT02633943Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

N/A

No Intervention

Beta-Thalassemia

N/A

Clinical Trials (1)

NCT06271512A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

N/A

Allo-HSCT

X-Linked Adrenoleukodystrophy (X-ALD)

N/A

Clinical Trials (1)

NCT02204904Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

N/A

No Intervention

Cerebral Adrenoleukodystrophy (CALD)

N/A

Clinical Trials (1)

NCT06224413A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

N/A

No interventional drug product utilized in this follow-up study

Cerebral Adrenoleukodystrophy (CALD)

N/A

Clinical Trials (1)

NCT02698579Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

N/A

bb2121

Multiple Myeloma

PHASE_1

Autologous EBV-CTL transduced with vector SFG-CNA12

Post-transplant Lymphoproliferative Disease

PHASE_1

Clinical Trials (1)

NCT03131934Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant

Phase 1

LentiGlobin BB305 Drug Product

Beta-Thalassemia Major

PHASE_1_2

Clinical Trials (1)

NCT02151526A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

Phase 1/2

LentiGlobin BB305 Drug Product

β-thalassemia Major

PHASE_1_2

Clinical Trials (1)

NCT01745120A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

Phase 1/2

lovo-cel

Sickle Cell Disease

PHASE_1_2

Clinical Trials (1)

NCT02140554A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

Phase 1/2

Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a

Sickle Cell Disease

PHASE_2

Clinical Trials (1)

NCT05353647A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)

Phase 2

MGTA-145

Sickle Cell Disease

PHASE_2

Clinical Trials (1)

NCT05445128Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Phase 2

Lenti-D Drug Product

Cerebral Adrenoleukodystrophy (CALD)

PHASE_2_3

Clinical Trials (1)

NCT01896102A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Phase 2/3

LentiGlobin BB305 Drug Product

Beta-Thalassemia

PHASE_3

Clinical Trials (1)

NCT02906202A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

Phase 3

LentiGlobin BB305 Drug Product

Beta-Thalassemia

PHASE_3

Clinical Trials (1)

NCT03207009A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

Phase 3

bb1111

Sickle Cell Disease

PHASE_3

Clinical Trials (1)

NCT04293185A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

Phase 3

Lenti-D

Cerebral Adrenoleukodystrophy (CALD)

PHASE_3

Clinical Trials (1)

NCT03852498A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Phase 3

Interview Prep Quick Facts

Portfolio: 18 clinical trials

Top TAs: Hematology, Rare Diseases

Open Roles: 20 active jobs

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Hematology

6 pipeline

Rare Diseases

6 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Genetix Biotherapeutics

Should You Work at Genetix Biotherapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (20)

Director of Scientific Communications & Evidence Generation

Director, Regulatory Labeling, Advertising and Promotion

Lead Specialist, QA Operations Lot Disposition

Sr. Manager, CMC Project Management

QA Manager, Qualified Treatment Center Oversight

QA Manager, Training (LMS)

Manager, Quality Systems

Sr. Manager, R&D Quality

Director, Apheresis Operations

Manager, Gene Therapy Operations (GTO)

Manager, Gene Therapy Operations (GTO)

Sr. Director, Regulatory CMC

Sr. Director Analytical Sciences

Manager, Cost Accounting

Sr. Process Engineer, MS&T LVV Manufacturing

Sr. Director Marketing

National Account Executive

Account Manager, Gene Therapy (New England)

Regional Medical Director

Head of Product/Portfolio Management

Hiring Trend